Anti-Atezolizumab Neutralizing Antibody ELISA kit

Catalog No.

KAJ70153

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

15.625-1,000 ng/ml

Precision

CV<20%

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Alternative Names

MPDL3280A,RG7446, CAS: 1380723-44-3

Tumor steatosis and glutamine synthetase expression in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy., PMID:37300323

Atezolizumab-induced psoriasiform drug eruption successfully treated with ixekizumab: a case report and literature review., PMID:37040912

Immunotherapies for advanced hepatocellular carcinoma., PMID:37025485

Allelic variation in HLA-DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro., PMID:35263013

Emerging immunotherapy for HCC: A guide for hepatologists., PMID:35253934

Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2)., PMID:34582105

Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)., PMID:34432389

Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer., PMID:34253638

Advances in immunotherapy for hepatocellular carcinoma., PMID:33850328

Detecting Immune Response to Therapies Targeting PDL1 and BRAF by Using Ferumoxytol MRI and Macrin in Anaplastic Thyroid Cancer., PMID:33107799

EpCAM Signaling Promotes Tumor Progression and Protein Stability of PD-L1 through the EGFR Pathway., PMID:32978170

Document Download

Anti-Atezolizumab Neutralizing Antibody ELISA kit.pdf